AOBO Launches New OTC Product to Treat Throat Inflammation
September 11 2009 - 9:00AM
PR Newswire (US)
- Launches YYQH Capsules Under Established Boke Brand - NEW YORK,
Sept. 11 /PRNewswire-Asia/ -- American Oriental Bioengineering,
Inc. (NYSE:AOB), ("the Company" or "AOBO"), a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter ("OTC") products, today announced that the
Company has launched a new product called YuYeQingHuo Capsules
("YYQH"). YYQH will be manufactured by the Company's Boke
subsidiary, and will be marketed throughout China utilizing AOBO's
distribution network, including the Company's national hospital and
pharmacy distribution network. YYQH capsules are a plant-based over
the counter medicine used to alleviate pain and inflammation
related to laryngitis, acute pharyngitis and acute aphonia. AOBO
believes that the market to address laryngitis-related symptoms is
currently underserved. Mr. Tony Liu, Chairman and Chief Executive
Officer of American Oriental Bioengineering, commented, "We are
pleased to demonstrate our new product launch capabilities today.
Our extensive network of more than 2,000 sales and marketing
professionals, in tandem with our R&D efforts and robust
product pipeline, allows AOBO to drive growth from new product
sales. This is particularly important as we navigate the changing
regulatory landscape in China. We are also excited about today's
launch because the YYQH capsules further enhance our market-leading
Boke products and brand and we believe that our YYQH capsules
address a niche market with no clear market leader as of now. We
remain confident in our future growth prospects as we continue to
expand our product lines and launch innovative new products." About
American Oriental Bioengineering, Inc. American Oriental
Bioengineering, Inc. is a pharmaceutical company dedicated to
improving health through the development, manufacture and
commercialization of a broad range of prescription and over the
counter products. Statements made in this press release are
forward-looking and are made pursuant to the safe harbor provisions
of the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties that may cause actual results to
differ materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended
December 31, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
DATASOURCE: American Oriental Bioengineering, Inc. CONTACT: Ashley
M. Ammon of Integrated Corporate Relations, Inc., +1-203-682-8200
Copyright